ConductScience.org, home

Paper41375124

Design, Synthesis, Molecular Docking, and Anticancer Activity of Chalcone Derivatives as VEGFR-2 Inhibitors.

Yu M and 3 others. Molecules, 2025. Cited by 3 papers, by iCite.

Cite this record

ConductScience Library. Design, Synthesis, Molecular Docking, and Anticancer Activity of Chalcone Derivatives as VEGFR-2 Inhibitors. Papers, record 41375124. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41375124

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Design, Synthesis, Molecular Docking, and Anticancer Activity of Chalcone Derivatives as VEGFR-2 Inhibitors.
PubMed
Journal
Molecules
PubMed
Year
2025
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
3
iCite
Revised in PubMed
2025-12-14
PubMed

Authors4

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Yu MMingjunhttps://orcid.org/0000-0003-1029-5538
2Zhang XXinhttps://orcid.org/0009-0004-3816-2264
3Zhu HHui
4Zhang XXiaoqian

Source PubMed

Download CSV of authors

Topics15

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Vascular Endothelial Growth Factor Receptor-2Major topic
Antineoplastic AgentsMajor topic
Drug DesignMajor topic
ChalconesMajor topic
Protein Kinase InhibitorsMajor topic
ChalconeMajor topic
Molecular Docking Simulation
Humans
Cell Line, Tumor
Apoptosis
Structure-Activity Relationship
Cell Proliferation
Drug Screening Assays, Antitumor
Molecular Structure
Animals

Source PubMed

Download CSV of topics

Grants4

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
BYKQ202417Bozhou University Research Initiation ProgramPubMed
BYH2025020Bozhou University Enterprise Cooperation ProjectPubMed
2022XJXM057Bozhou University Teaching Reform ProgramPubMed
2024jsqygz135Anhui Province University Science and Engineering Teachers' Internship Program in EnterprisesPubMed

Source PubMed

Download CSV of grants

References47

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
139138146Therapeutic advances of targeting receptor tyrosine kinases in cancer.Signal Transduct Target Ther2024https://conductscience.org/library/papers/39138146PubMed
233076807Tumor Angiogenesis and VEGFR-2: Mechanism, Pathways and Current Biological Therapeutic Interventions.Curr Drug Metab2021https://conductscience.org/library/papers/33076807PubMed
320629091Targeted molecular therapy of head and neck squamous cell carcinoma with the tyrosine kinase inhibitor vandetanib in a mouse model.Head Neck2011https://conductscience.org/library/papers/20629091PubMed
412094254Overexpression of vascular endothelial growth factor (VEGF) and its cellular receptor KDR (VEGFR-2) in the bone marrow of patients with acute myeloid leukemia.Leukemia2002https://conductscience.org/library/papers/12094254PubMed
533670650Molecular Targeting of Epidermal Growth Factor Receptor (EGFR) and Vascular Endothelial Growth Factor Receptor (VEGFR).Molecules2021https://conductscience.org/library/papers/33670650PubMed
635820328New fluorinated diarylureas linked to pyrrolo[2,3-d]pyrimidine scaffold as VEGFR-2 inhibitors: Molecular docking and biological evaluation.Bioorg Chem2022https://conductscience.org/library/papers/35820328PubMed
738969664A comprehensive review of computational cell cycle models in guiding cancer treatment strategies.NPJ Syst Biol Appl2024https://conductscience.org/library/papers/38969664PubMed
833536909Pharmacological Properties of Chalcones: A Review of Preclinical Including Molecular Mechanisms and Clinical Evidence.Front Pharmacol2020https://conductscience.org/library/papers/33536909PubMed
935799213Recent progress on vascular endothelial growth factor receptor inhibitors with dual targeting capabilities for tumor therapy.J Hematol Oncol2022https://conductscience.org/library/papers/35799213PubMed
1033171134Antioxidant and anti-inflammatory effects of hesperidin methyl chalcone in experimental ulcerative colitis.Chem Biol Interact2021https://conductscience.org/library/papers/33171134PubMed
1136186578Urea-based anticancer agents. Exploring 100-years of research with an eye to the future.Front Chem2022https://conductscience.org/library/papers/36186578PubMed
1236335233The use of machine learning modeling, virtual screening, molecular docking, and molecular dynamics simulations to identify potential VEGFR2 kinase inhibitors.Sci Rep2022https://conductscience.org/library/papers/36335233PubMed
1334043477An updated patent review of VEGFR-2 inhibitors (2017-present).Expert Opin Ther Pat2021https://conductscience.org/library/papers/34043477PubMed
1433476864
Design and synthesis of methoxyphenyl- and coumarin-based chalcone derivatives as anti-inflammatory agents by inhibition of NO production and down-regulation of NF-κB in LPS-induced RAW264.7 macrophage cells.
Bioorg Chem2021https://conductscience.org/library/papers/33476864PubMed
1537338020Synthesis, reactions and application of chalcones: a systematic review.Org Biomol Chem2023https://conductscience.org/library/papers/37338020PubMed
1638281295
Rivoceranib, a VEGFR-2 inhibitor, monotherapy in previously treated patients with advanced or metastatic gastric or gastroesophageal junction cancer (ANGEL study): an international, randomized, placebo-controlled, phase 3 trial.
Gastric Cancer2024https://conductscience.org/library/papers/38281295PubMed
1736555234The VEGF/VEGFR Axis Revisited: Implications for Cancer Therapy.Int J Mol Sci2022https://conductscience.org/library/papers/36555234PubMed
1838370458New pyrazolylindolin-2-one based coumarin derivatives as anti-melanoma agents: design, synthesis, dual BRAFV600E/VEGFR-2 inhibition, and computational studies.RSC Adv2024https://conductscience.org/library/papers/38370458PubMed
1935109719Angiogenesis and anti-leukaemia activity of novel indole derivatives as potent colchicine binding site inhibitors.J Enzyme Inhib Med Chem2022https://conductscience.org/library/papers/35109719PubMed
2033972962Naturally occurring prenylated chalcones from plants: structural diversity, distribution, activities and biosynthesis.Nat Prod Rep2021https://conductscience.org/library/papers/33972962PubMed

See all 47 referencesDownload CSV of references

Cited by1

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 3 citations.

PMIDTitleJournalYearIn Papers
42548118Recent Progress in Urea-Containing Compounds as Tyrosine Kinase Inhibitors.Chem Biodivers2026https://conductscience.org/library/papers/42548118

Source PubMed

Download CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
KDR3791PubTator's text mininghttps://conductscience.org/library/genes/3791

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/41375124

GET https://conductscience.org/api/papers/v1/41375124/references?page=2